Effects of Cocoa on Gastrointestinal Function
Effects of Cocoa Solids on Gastrointestinal Transit, Postprandial Sensation and Gastrointestinal Well-being: a Randomized, Controlled Trial in Healthy Volunteers
1 other identifier
interventional
16
1 country
1
Brief Summary
This is a randomized, controlled, 2x2 cross-over study to assess the effects of cocoa solids on gastrointestinal transit, post-prandial sensation and well-being. Additionally functional brain imaging will be applied to identify regions of brain that are activated or inactivated by cocoa ingestion. Healthy subjects will be recruited and randomized to receive either dark chocolate (70% cocoa solids) or white chocolate (0% cocoa solids) in addition to their normal diet in randomized order. Reference standard methodology will be applied to measure gastric emptying, oro-caecal and colonic transit time. Dark and white chocolate (100g, \~500kcal, \~50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity using FDG-Positron Emission Tomography. Additionally colonic transit will be assessed based on the number and distribution of radio-opaque markers in the colon. On the fourth day gastric emptying and oro-caecal transit time will be assessed by scintigraphy after ingestion of a dark or white chocolate mousse test meal (both 150g, \~500kcal, \~50% fat). During both interventional studies pre- and post-prandial satiety and dyspeptic symptoms, well-being and mood will be recorded. Additionally, validated questionnaires will assess digestive comfort and well-bring at the end of each study day. These results will deliver comprehensive information about the effects of cocoa on gastrointestinal transit and sensation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2017
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
January 10, 2017
CompletedFirst Posted
Study publicly available on registry
January 18, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2017
CompletedFebruary 12, 2018
February 1, 2018
5 months
January 10, 2017
February 9, 2018
Conditions
Outcome Measures
Primary Outcomes (1)
Gastric emptying half time
assessed by scintigraphy
Baseline until 2 hours postingestion
Secondary Outcomes (4)
Oro-caecal transit time (OCTT)
Baseline until 3 hours postingestion
Colonic transit time
Baseline until 3 days after ingestion
Post-prandial satiety
changes from baseline to three hours after treatment
Gastrointestinal well-being
changes from baseline to three hours after treatment
Study Arms (4)
Dark chocolate: FDG-PET
ACTIVE COMPARATOR100 g dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using chocolate: fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
Dark chocolate: Physiological Measurement
ACTIVE COMPARATOR150 g dark chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
White chocolate: FDG-PET
PLACEBO COMPARATOR100 g white chocolate bar (0% cocoa solids (\~500kcal, 50% fat) will be consumed with radio-opaque markers on three consecutive days. On the third day chocolate ingestion will be followed by measurements of postprandial brain activity and colonic transit using FDG-Positron Emission Tomography.
White chocolate: Physiological Measurement
PLACEBO COMPARATOR150 g white chocolate mousse (\~500kcal, \~50% fat) labelled with 13C-lactose-ureide and technetium (99Tc) will be consumed to assess gastric emptying and oro-caecal transit time by scintigraphy.
Interventions
Dark chocolate bar (70% cocoa solids (\~500kcal, \~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
Dark chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
White chocolate bar (0% cocoa solids (\~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
White chocolate mousse (150g, \~500kcal, \~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
Eligibility Criteria
You may qualify if:
- Healthy volunteers (men and women)
- aged 18-65 years
- body mass index 18-30kg/m2.
You may not qualify if:
- special dietary requirements incompatible with dietary intervention (food allergies or intolerances)
- clinically significant concomitant disease states (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.) that preclude intake of test meals
- participation in another study with investigational drug within the 30 days preceding and during the present study (purely diagnostic studies are acceptable)
- individuals unwilling to provide written informed consent
- inability to follow the procedures of the study, e.g. due to language problems (all study documents in English)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
St Claraspital
Basel, 4016, Switzerland
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Fox, Prof. Dr.
St. Claraspital Basel, Abdominal Center: Gastroenterology
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 10, 2017
First Posted
January 18, 2017
Study Start
January 1, 2017
Primary Completion
June 1, 2017
Study Completion
June 1, 2017
Last Updated
February 12, 2018
Record last verified: 2018-02